Abstract:Objective To explore clinical effect of Palmer Fu Lin Capsules combined with Methotrexate in the treatment of Sjögren syndrome(SS).Methods 100 patients with SS were selected as the research object in the Shenzhen Hospital of Peking University from February 2014 to May 2016 and divided into control group and combined treatment group according to treatment measures,50 cases in each group.The control group were treated with methotrexate 2.5 mg/tablet, each time 4 tablets,1 time a week;the combined treatment group were treated with Palmer Fu Lin Capsules each time 2 tablets,2 times/d on the basis of the control group,patients of two groups were treated for 6 months.Rheumatoid factor (RF),ESR,C reactive protein(CRP),salivary flow rate,Schirmer test,serum γ-globulin,blood coagulation index level before and after treatment,and clinical curative effect were compared between two groups.Results RF,ESR,CRP,saliva flow rate,Schirmer test,serum γ-globulin,activated partial thromboplastin time(APTT),prothrombin time(PT),fibrinogen (FIB),thrombin time(TT),D-Dimer(D-D)between two groups before treatment had no difference(P>0.05).APTT,PT,TT in two groups before and after treatment had no difference(P>0.05);RF,ESR,CRP,saliva flow rate,Schirmer test,serum γglobulin,FIB,D-D after treatment in two groups was lower than that before treatment(P<0.05).RF,ESR,CRP,saliva flow rate,Schirmer test,serum γ-globulin,FIB,D-D of the combined treatment group was lower than that of the control group (P<0.05).The total effective rate of the combined treatment group was higher than that of the control group,the difference was statistical significance(P<0.05).Conclusion Clinical symptoms of Palmer Fu Lin Capsules combined with Methotrexate in the treatment of(SS)improve obviously,clinical effect is good,it is worthy of clinical application.
陈澄;杨智;蔡月明. 帕夫林胶囊联合甲氨蝶呤治疗干燥综合征的临床观察[J]. 中国当代医药, 2017, 24(7): 29-31转34.
CHEN Cheng;YANG Zhi;CAI Yue-ming. Clinical observation of Palmer Fu Lin Capsules combined with Methotrexate in the treatment of Sjögren syndrome. 中国当代医药, 2017, 24(7): 29-31转34.
Juarez M,Toms TE,de Pablo P,et al.Cardiovascular risk factors in women with primary Sjögren′s syndrome:United Kingdom primary Sjögren′s syndrome registry results[J]. Arthritis Care Res(Hoboken),2014,66(5):757-764.
O′Connor CR.Systematic review of the presentation of coagulation factorⅧinhibitors in rheumatic diseases:a potential cause of life-threatening hemorrhage[J].Semin Arthritis Rheum,2015,44(6):695-709.
Senchenkova E,Seifert H,Granger DN.Hypercoagu lability and platelet abnormalities in inflammatory bowel disease[J]. Semin Thromb Hemost,2015,41(6):582-589.
[14]
Witkowski M,Landmesser U,Rauch U.Tissue factor as a link between inflammation and coagulation[J].Trends Cardiovasc Med,2016,26(4):297-303. 280例[J].实用医学杂志,2016,32(12):2028-2030.